The Claim
Once-weekly subcutaneous semaglutide 2.4 mg is associated with a higher incidence of gastrointestinal adverse events (nausea, vomiting, diarrhea, and constipation) compared to placebo in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stage 2 or 3, with no increase in serious adverse events.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Patients with MASH and moderate liver fibrosis who take weekly semaglutide injections have more gastrointestinal side effects like nausea and diarrhea than those taking a placebo. However, the rate of serious adverse events is not higher with semaglutide.
See the scientific wording
Gastrointestinal adverse events (including nausea, vomiting, diarrhea, and constipation) are more common with once-weekly subcutaneous semaglutide 2.4 mg than with placebo in patients with MASH and fibrosis stage 2 or 3, consistent with the known safety profile of GLP-1 receptor agonists, though no increase in serious adverse events was reported.
Semaglutide slows down stomach emptying and makes you feel full longer by activating receptors in the gut and brain. This causes the stomach to empty slowly, leading to nausea and vomiting, and can also affect bowel movements causing diarrhea or constipation.
What the research says
1 studyStudy: Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
The study found that people taking semaglutide had more stomach-related side effects like nausea and diarrhea than those on placebo, just like the claim says. This is expected for this type of medicine.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.